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Very small embryonic-like stem cells (VSELs) represent a unique rare population of adult stem cells (SCs) sharing several structural,
genetic, biochemical, and functional properties with embryonic SCs and have been identified in several adult murine and human
tissues. However, rat bone marrow- (BM-) derived SCs closely resembling murine or human VSELs have not been described.Thus,
we employed multi-instrumental flow cytometric approach including classical and imaging cytometry and we established that
newly identified population of nonhematopoietic cells expressing CD106 (VCAM-I) antigen contains SCs with very small size,
expressing markers of pluripotency (Oct-4A and Nanog) on both mRNA and protein levels that indicate VSEL population. Based
on our experience in both murine and human VSEL isolation procedures by fluorescence-activated cell sorting (FACS), we also
optimized sorting protocol for separation of CD45−/Lin−/CD106+ rat BM-derived VSELs fromwild type and eGFP-expressing rats,
which are often used as donor animals for cell transplantations in regenerative studies in vivo. Thus, this is a first study identifying
multiantigenic phenotype and providing sorting protocols for isolation VSELs from rat BM tissue for further examining of their
functional properties in vitro as well as regenerative capacity in distinct in vivo rat models of tissue injury.
1. Introduction
Flow cytometric platforms have been well established as
valuable tools for identification and isolation of several cell
populations based on theirmultiantigenic profile [1–4]. Based
on advanced modified and optimized FACS protocols, we
have identified and sorted new fractions of rare stem cells
(SCs) including very small embryonic-like stem cells (VSELs)
that reside predominantly in bone marrow (BM) but also in
other tissues such fetal liver, umbilical cord blood (UCB),
and multiple adult specimens harvested from various organs
and tissues [2, 3, 5]. The major impact of our experience in
this subject was the implementation of challenging methods
for purification of such unique rare fractions of SCs based
on their multiantigenic profile by modern flow cytometric
platforms.
Recently, numerous reports have shown that adultmurine
as well as human specimens such as BM, peripheral blood
(PB), solid organs, and UCB may contain primitive stem
cell fractions with multi- and pluripotent characteristics.
Such SCs populations include unrestricted somatic stromal
cells (USSCs) [6], multilineage-differentiating stress-endur-
ing (Muse) cells [7, 8], marrow-isolated adult multilineage
inducible cells (MIAMI) [9], multipotent adult progenitor
cells (MAPCs) [10], multipotent adult stem cells (MASCs)
[11], and a population of VSELs [12–14].
VSELs represent a unique rare population of adult SCs
sharing several structural, genetic, biochemical, and func-
tional properties with embryonic SCs and have been iden-
tified in several adult murine and human tissues includ-
ing ovaries and testes [15–22]. Murine VSELs defined rep-
resenting small-sized cells expressing Sca-1 antigen but
not expressing CD45 and hematopoietic lineages mark-
ers (FSClow/SSClow/CD45−/Lin−/Sca-1+) have been initially
identified in murine BM and subsequently found in several
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other adult murine organs as rare population of SCs [23–
25]. Genetic analysis such as real-time RT-PCR in sorted
murine FSClow/SSClow/CD45−/Lin−/Sca-1+ cells has showed
the increased levels of mRNA for embryonic stem cells mark-
ers such as SSEA-1, Oct-4, Nanog, and Rex-1 (Rexo1) that
was also confirmed onprotein level using immunofluorescent
staining and ImageStream system imaging (ISS) [23, 26].
Importantly, detailed molecular and genetic analysis of these
cells reveled their (1) hypomethylated promoters for Oct-4
and Nanog transcription factors and (2) unique epigenetic
status including hypomethylation of growth-repressive H19
gene along with hypermethylation of growth-promoting Igf-
2 gene that leads to in inhibition of proliferation of these cells
and limits their tumorigenic and blastocyst complementation
capacity [27]. Importantly, the presence of VSELs in several
other murine and human tissues including ovaries and testes
has been also confirmed by other investigators [17–19, 21, 22,
28–30].
Human UCB- and PB-derived VSELs are phenotypically
similar to those described in adult murine BM and may
be also identified within nonhematopoietic compartments
(CD45−/Lin−) of such specimens, especially among small-
sized objects (FSClow/SSClow). Human VSELs are also very
small in diameter and are smaller than red blood cells
(RBCs), which is a unique feature for these stem cells along
all investigated species. The population of Oct-4-, Nanog-,
and SSEA-4-expressing VSELs in humans is enriched among
CD45−/Lin− fraction carrying CD133/1 (AC133), CD34, or
partially CXCR4 [3, 4, 14]. Although the human VSELs
have been initially characterized as cells expressing CXCR4
receptor, we further established that the fraction enriched
in Oct-4, SSEA-4 expressing cells that possess very small
size and high N/C ration, may be predominantly found
in CD45−/Lin−/CD133+ population of UCB-derived cells
[3, 31]. Such cell expressed early embryonic transcription
factors as Oct-4 and Nanog, at both mRNA and protein
levels as confirmed by quantitative RT-PCR and imag-
ing cytometry, respectively [31]. Since then, we consider
the CD45−/Lin−/CD133+ population as mostly enriched
in VSELs. Importantly, cytometric characteristics of UCB-
derived SCs revealed normal diploid (2n) content of DNA in
both VSELs andHSCs fractions in the G0/G1 phase of the cell
cycle [32].
Distinct “positive markers” have been identified for
VSELs isolated fromdifferent species. In our previous studies,
we have identified only limited number of such selection
markers present on VSEL surface including Sca-1 antigen in
mice and CD34 or CD133 in humans [32]. These findings
indicate that the expression of thesemarkers is species-related
and there is no VSEL-specific surface antigen identified for
all species up to today. Moreover, Sca-1 antigen representing
murine VSELs selection marker is not present on human or
rat cell, while CD34 antigen commonly present on human
stemandprogenitor cells has been rarely identified onmurine
or rat stem cells. Importantly, the positive selection markers
for VSELs have not been identified within MSC-specific
markers such as CD29 and CD105 [1, 7]. However, our
long term observations of murine and human VSELs in in
vitro culture strongly suggest their high adhesive properties.
Such functional properties correspond to the expression of
several adhesion molecules and receptors including CD54,
CD106, and members of 𝛼-integrin family (e.g., CD49f) that
were detected on murine VSEL surface by our group and
also by Professor Ratajczak and his colleagues, but these
important data are still unpublished. However these findings
may suggest that the adhesion molecules and receptors may
be group harboring selection markers for VSEL isolation that
was considered in this study.
Although both murine and human VSELs have been
well characterized on phenotypical and genetic levels, such
primitive SCs in other mammals including rats have been
poorly investigated. The first study questing for VSELs coun-
terpart in rat BM was performed by Wu and colleagues who
described a population of CD45−/Lin− (Ter-119−, CD11b−,
and Gr-1−)/SSEA-1+ cells in this tissue. Although the Sca-1
antigen has been identified specifically on murine, but not
rat or human cells, the authors reported existence of such rat
SSEA-1+ VSELs expressing Sca-1 and also PSC transcriptional
factors such as Oct-4, Nanog, Rex-1, Sox-2, and Fgf-4 in
murine bone marrow [33].
Thus, the aim of our study was to identify and purify
enriched population of rat VSELs (rVSELs) derived from
adult rat BM based on phenotypic and antigenic similarity
to murine VSELs and selected antigen expression (CD54
and CD106) with using only specifically anti-rat reagents
and by employing both classical and imaging flow cytometry
(ImageStream X system, ISS-X). Moreover, the goal was to
optimize flow cytometric sorting strategies for purification of
rVSELs derived from wild type (WT) and eGFP-expressing
transgenic Wistar rats that may be further employed in
in vitro and preclinical studies identifying their functional
potential.
2. Materials and Methods
2.1. Animals. Experimental procedures involving animal
material were performed in accordance with the national and
European legislation following approval by the First Local
Ethical Committee on Animal Testing at the Jagiellonian
University in Krakow (approval number: 56/2009). Two
strains of Wistar rats, (1) WT (Crl: WT) and (2) transgenic
eGFP-expressing rats (Wistar-TgN(CAG-GFP)184Ys), were
purchased from National Bio Resource Project for the Rat
in Japan, Kyoto University, and supplied by the experimental
animal facility from Nencki Institute of Experimental Biol-
ogy, Polish Academy of Sciences, Warsaw, Poland.
2.2. BM Cells Preparation. BM tissue was isolated from adult
(8–12-week-old)WT and transgenic eGFP-expressingWistar
rats by flashing of cavities of tibias and femurs. BM cell
suspensions were collected and filtered through a 70-𝜇m
strainer (BD Bioscience). Total nucleated cells (TNCs) were
obtained following lysis of red blood cells (RBCs) with 1x BD
Pharm Lyse Buffer (BD Pharmingen) for 10 minutes. TNCs
were subsequently washed with phosphate buffered saline
(DPBS; w/o Ca2+, Mg2+; Life Technologies) and resuspended
in DMEM-based staining medium (Sigma-Aldrich, St. Louis,
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MO) containing 2% of fetal bovine serum (FBS) (Lonza,
Basel, Switzerland) for further analyses.
2.3. Staining for Flow Cytometric Analysis and FACS Sorting.
TNCs harvested from both Wistar strains were immuno-
labeled with the following monoclonal antibodies: Alexa
Fluor 647- or PE-Cy7-conjugated anti-CD45 (clone: OX-
1; BioLegend), Alexa Fluor 647- or FITC-conjugated anti-
hematopoietic lineages markers cocktail—“Lin” markers,
including anti-TCR𝛼𝛽 (clone: R73), anti-CD3 (clone: 1F4),
anti-CD11b/c (clone: OX-42), and anti-CD45RA (clone: OX-
33); BD Pharmingen and BioLegend, PE-conjugated anti-
CD54 (clone: 1A29; BD Pharmingen), and PE- or biotin-
conjugated anti-CD106 (PE, clone: MR-106; BioLegend).
Streptavidin with PerCp-Cy5.5 (BD Pharmingen) was added
to the samples to visualize the binding of biotin-conjugated
anti-CD106 antibody. All antibodies were used according
to manufacturer’s protocols and staining was performed for
30min at 4∘C. Cells were subsequently washed and resus-
pended in DMEM with 2% FBS for further flow cytometric
analysis (LSR II; Becton Dickinson) or sorting procedure
(MoFlo XDP; BeckmanCoulter).
Rat BM-derived VSEL population was considered to
be enriched in FSClow/SSClow/CD45−/Lin− cells expressing
CD54 or/and CD106 antigens.
To compare the status of the sorted rVSELs with
CD45−/Lin−/SSEA-1+ population identified byWu et al. [33],
TNC fraction was stained for CD45 and Lin markers (as
described above) and additionally with directly conjugated
anti-mouse/human SSEA-1 antibody (PE, clone: MC-480,
BioLegend). We used directly conjugated anti-SSEA-1 anti-
body to prevent nonspecific background staining crucial to be
avoided in sorting of rare cell populations. All used antibodies
are described in Table 1.
2.4. Staining for ImageStream X System (ISS-X) Analy-
sis. For rVSELs identification by ImageStream X system
(Amnis Corp.), TNCs derived for WT Wistar rats were
prepared according to the protocol described above. Based
on the detection channels available for the ISS-X, the
following directly conjugated monoclonal antibodies were
used for identification of small CD45−/Lin−/CD106+ and/or
CD45−/Lin−/CD54+ cells: (i) anti-CD45 (Alexa Fluor 647,
clone: OX-1), (ii) FITC-conjugated Lin markers (includ-
ing anti-TCR𝛼𝛽 (clone: R73), anti-CD3 (clone: 1F4), anti-
CD11b/c (clone: OX-42), anti-CD45RA (clone: OX-33)) (BD
Pharmingen), and (iii) CD106 (PE, clone: MR-106; BioLe-
gend) or (iv) CD54 (PE, clone: 1A29) (BD Pharmingen).
Staining was performed according to manufacturers’ proto-
cols for 30min at 4∘C. Samples were subsequently washed
and fixed with 4% of paraformaldehyde solution (Sigma) for
20min (RT). Fixed cells were resuspended in saline (DPBS;
w/o Ca2+, Mg2+; Life Technologies) in concentration of 2
× 106/mL for further analysis with ImageStream X system
(Amnis Corp.); Hoechst 33342 (Hoe; 2 𝜇M) was added for
10min prior to analysis to visualize nuclei.
In order to analyze intranuclear expression of pluripotent
markers such as Oct-4A and Nanog and to further identify
Oct-4A+ and/or Nanog+ rat BM-derived VSELs, freshly
Table 1: Antibodies employed in staining for identification and





Anti-CD45 OX-1 PE-Cy7/Alx647 BioLegend
Anti-𝛼𝛽-TCR R73 FITCAlx 647
BD Biosciences
BioLegend
Anti-CD2 OX-34 FITC BD Bioscience
Anti-CD3 1F4 FITCAlx 647
BD Bioscience
BioLegend












Streptavidin — PerCp-Cy5.5 BD Bioscience
Anti-SSEA-1 MC-480 PE BioLegend
isolated TNCs were initially fixed with 4% paraformaldehyde
(Sigma) for 20min (RT) and subsequently permeabilized
with 0.1% Triton X-100 solution (Sigma) for 10min (RT).
Cells were further washed and stained either with (i) primary
anti-Oct-3/4 antibody (rabbit polyclonal IgG, Santa Cruz
Biotechnology, sc-9081, CA, USA, 1 : 100) that specifically
stains Oct-4A isoform identifying PSCs or (ii) primary anti-
Nanog antibody (rabbit polyclonal IgG, Santa Cruz Biotech-
nology, sc-33760, 1 : 100) for 2 h at 37∘C. Secondary goat anti-
rabbit IgG antibody conjugated with Alexa Fluor 488 or
Alexa Fluor 647 (Invitrogen, Molecular Probes, Carlsbad,
Ca, USA, 1 : 200) was added for 2 h (37∘C). Cells were
washed following the staining for Oct-4A and Nanog and
subsequently incubated with directly conjugated antibodies
against (i) CD106-PE,CD45-PE-Cy7, or FITC-conjugated Lin
markers (including TCR𝛼𝛽, CD3, CD11b, and CD45RA) for
30min at 4∘C. Cells were further washed and resuspended
in DPBS (w/o Ca2+, Mg2+; Life Technologies). Nuclei were
stained with Hoechst 33342 (Hoe) directly before analysis
and samples were further analyzed with ImageStream X
system (Amnis Corporation, Seattle, WA, USA). Analyses of
morphological features of selected BM-derived populations
were performed based on the collected images with IDEAS
analytical software (Amnis Corporation, Seattle, WA, USA).
2.5. Gene Expression Analysis by Real-Time RT-PCR.
Total RNA from sorted subpopulations of CD45−/
Lin−/CD106+/CD54+, CD45−/Lin−/CD106+, and CD45−/
Lin−/SSEA-1+ cells as well as from their hematopoietic coun-
terparts (CD45+/Lin−/CD106+/CD54+ and CD45+/Lin−/
CD106+) was isolated using the RNeasy Micro Kit (Qiagen,
Valencia, CA). mRNA was further reversely transcribed
into cDNA with TaqMan Reverse Transcription Reagents
(Applied Biosystems, Foster City, CA,USA) and the reactions
were performed under the following conditions: 1 cycle at
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25∘C for 10min, 1 cycle at 48∘C for 30min, and finally 1 cycle
at 95∘C for 5min. mRNA harvested from unfractionated
TNCs was used as control (called “input”). 50 ng of total
RNA was used for each reverse transcription reaction.
Detection of expression of the following rat genes𝛽-actin,
Oct-4, Nanog, and Rexo1 was performed by real-time RT-
PCR using an ABI PRISM 7000 sequence detection system
(Applied Biosystems). A 25-𝜇L reaction mixture contained
12.5 𝜇L SYBR Green PCR Master Mix (Applied Biosystems),
cDNA template (2,5 ng), and both forward (1 𝜇M) and reverse
(1 𝜇M) primers (TibMolBiol, Poznan, Poland).The following
sequences of primers were used: 𝛽-actin: (F) 5󸀠- TGA CCC
AGA TCA TGT TTGAGA -3󸀠, (R) 5󸀠- CAAGGTCCAGAC
GCA GGA T-3󸀠; Oct-4: (F) 5󸀠- CCC AGC GCC GTG AAG
TTGGA -3󸀠, (R) 5󸀠- AGAACGCCCAGGGTGAGCCC -3󸀠;
Nanog: (F) 5󸀠- CCC TTG CCG TTG GGC TGA CA -3󸀠, (R)
5󸀠- AAGGCGGAGGAGAGGCAG TCT -3󸀠; Rexo-1 (F) 5󸀠-
GCT CCG GCG GAA TCG AGT GG -3󸀠, (R) 5󸀠- GCA CGT
GTT GCT TGG CGA CC -3󸀠.
Real-time RT-PCR reactions were performed under the
following conditions: 1 cycle at 50∘C for 2min, 1 cycle at 95∘C
for 10min, followed by 40 cycles at 95∘C for 15 s, and 60∘C
for 1min. Relative quantification of Oct-4, Nanog, and Rexo1
mRNA expression was calculated using the comparative Ct
method.The relative quantitative value of the target, normal-
ized to an endogenous control (𝛽-actin gene) and relative
to a calibrator, was expressed as 2−ΔΔCt (i.e., fold difference),
where ΔCt = [Ct of target genes] − [Ct of endogenous control
gene] and ΔΔCt = [ΔCt of samples for target genes] − [ΔCt of
calibrator for target gene].
To avoid the possibility of amplifying contaminating
DNA, the following steps were taken: (i) all primers were
designed with an intron sequence inside the cDNA to be
amplified; (ii) all reactions were performed with an appropri-
ate negative controls (template-free controls); (iii) a uniform
amplification of the products was rechecked by analyzing
the melting curves of the amplified products (dissociation
graphs).
2.6. Immunocytochemistry. To evaluate Oct-4A and Nanog
expression in purifiedBMsubpopulation, the limited number
of sorted cells (10×103) was seeded on poly-L-lysine (Sigma)
coated glass-bottom plates (Willco-dish, Willco Wells B.V.)
in medium DMEM with 2% FBS (Lonza) and was incubated
overnight in standard culture conditions. The medium was
subsequently removed and the attached cells were gently
fixedwith 4%paraformaldehyde (Sigma) for 20min (RT) and
subsequently permeabilized with 0.1% Triton X-100 solution
(Sigma) for 10min (RT). Cells were washed and stained either
with (i) primary anti-Oct-3/4 antibody (rabbit polyclonal
IgG, Santa Cruz Biotechnology, sc-9081, CA, USA, 1 : 100)
that specifically stains Oct-4A isoform identifying PSCs or
(ii) primary anti-Nanog antibody (rabbit polyclonal IgG,
Santa Cruz Biotechnology, sc-33760, 1 : 100) for 16 h at 4∘C.
Secondary goat anti-rabbit IgG antibody conjugated with
Alexa Fluor 488 or Alexa Fluor 546 (Invitrogen, Molecular
Probes, Carlsbad, Ca, USA, 1 : 200) was added for 2 h (37∘C).
Cells were washed and nuclei were stained with 4󸀠, 6-
diamidino-2-phenylindole (DAPI, 2 𝜇M, Life Technologies,
Molecular Probes) for 15min (37∘C) and plates were closed
with VECTASHIELD Mounting Medium (Vector Laborato-
ries, CA, USA) and cover slips. Sorted CD45+/Lin−/CD106+
subpopulation of BM cells that represents hematopoietic
counterpart of purified CD45+/Lin−/CD106+ VSELs was also
stained for Oct-4A and Nanog and was used as negative
control in this setting. The labeled cells were subsequently
analyzed with Leica DMI6000B (ver. AF7000) fluorescent
microscope under total 945x magnification (Leica Microsys-
tems GmbH, Germany).
2.7. Statistical Analysis. Data were expressed as the mean ±
standard deviation (SD). A value of 𝑃 < 0.05 was considered
significant. All statistical analyses were performed using
the Origin (ver. 5.0) statistical software (Microcal Software,
Northampton, MA).
3. Results
3.1. Rat BM Harbors a Population of Very Small Non-
hematopoietic SCs Expressing CD54 and CD106 Antigen. Our
previously published data have indicated murine and human
VSELs represent populations of nonhematopoietic stem cells
with very small cells size which do not express markers of
hematopoietic lineages such as CD45 and major hematopoi-
etic lineage specific antigens [2, 3, 5]. Thus, in this study,
we started our quest for rat BM-derived VSELs focusing
on cells with corresponding characteristics by employing
multiparameter flow cytometric platforms. We focused on
CD45−/Lin− cells with small size and low cytoplasmic com-
plexity and volume, indicated as FSClow and SSClow objects,
respectively. Our second step was focused on “positive
selection” marker that would optimally define these unique
SCs. We have previously reported only limited number
of markers present on VSEL surface that may distinguish
them from other cell types such as Sca-1 antigen in mice
and CD34 or CD133 in humans [2, 3, 5]. Therefore, the
expression of VSEL “positive selection” markers is distinct
in different species and VSEL-specific surface antigen has
not been identified. However, our long term observations of
murine and human VSELs in in vitro culture indicate their
high adhesive properties which correspond to the expression
of several adhesion molecules and receptors including, for
example, CD54,CD106, andCD49f (unpublished data).Thus,
we focused on two molecules involved in cell adhesion as
potential markers for rVSELs including CD54 (ICAM-I) and
CD106 (VCAM-I).
We initially isolated BM cells from adult WT Wistar
rats and stained total nucleated cells obtained following
RBCs lysis to identify presence of CD45−/Lin−/CD54+ or
CD45−/Lin−/CD106+ cells by classical as well as imaging
cytometry (ISS-X) that allows for distinguishing real rare
cellular objects from artifacts.
By using both flow cytometric platforms, we found that
rat BM tissue contains both rare populations of very small
nonhematopoietic (CD45−/Lin−) cells expressing CD54 and
CD106 antigens (0.003 ± 0.001% and 0.011 ± 0.005%,
resp.) (Figure 1). Since we expected rVSELs to be small
size cells, we focused on gating events including those with


















































































































BF Lin CD106 Hoe CD45 Combo












Figure 1: Expression of CD54 (ICAM-I) and CD106 (VCAM-I) on rat BM cells. (a) Gating strategy for identification of CD54+ and CD106+
populations by classical flow cytometry. Total nucleated cells (TNCs) derived fromWTrat BMwere stained forCD45 (PE-Cy7), hematopoietic
lineages markers (Lin: TCR𝛼𝛽, CD3, CD11b, CD45RA; FITC), and CD54 (PE) or CD106 (PE) and further analyzed by LSR II (Becton
Dickinson). BM cells are visualized on dot-plot showing FSC versus SSC signals, which are related to the size and granularity/complexity
of the cell, respectively. 2% of total 1 × 106 of analyzed TNCs is only displayed in this dot-plot to visualize the population distribution.
Objects from region P1 (lymphgate including FSClow/SSClow objects) were further analyzed for Lin markers expression and only Lin−
events are included into region P2. Upper, middle dot-plot cells stained for CD54, derived from gate P2, and analyzed for CD54 versus
CD45 expression. Two fractions of cells potentially enriched in stem/progenitor cells are gated: rHSCs, CD45+/Lin−/CD54+ (region P3),
and rVSELs, CD45−/Lin−/CD54+ (region P4). Both populations are further “back-gated” on FSC versus SSC dot-plot to visualize cell size
distribution. Lower, middle dot-plot cells stained for CD106, derived from gate P2, and analyzed for CD106 versus CD45 expression; rHSC,
CD45+/Lin−/CD106+ (region P3), and rVSELs, CD45−/Lin−/CD106+ (region P4). Both populations are further “back-gated” on FSC versus
SSC dot-plot to visualize cell size distribution. Percentages show content of each subpopulation among TNCs in representative sample. Total
1 × 10
6 of TNCs was typically collected for each sample to identify the SC populations. (b) Representative images of nonhematopoietic cells
expressing CD54 and CD106 by ImageStream X system (ISS-X). TNCs were stained for Lin markers (FITC, green), CD45 (Alexa Fluor 647,
blue), CD54 (PE, orange), or CD106 (PE, orange). Cells were fixed and nuclei were stained with Hoechst 33342 prior to analysis by ISS.
Extracellular expression of CD106 and CD54 is shown on combo as well as on magnified images (right panels).The scale bars indicate 10 𝜇m.




































































Figure 2: Expression of mRNA for Oct-4, Nanog, and Rexo-1 by real-time RT-PCR in sorted fractions of BM cells. Indicated
populations of nonhematopoietic (CD45−/Lin−/CD106+, CD45−/Lin−/CD106+/CD54+, and CD45−/Lin−/SSEA-1+) and hematopoietic
(CD45+/Lin−/CD106+, CD45+/Lin−/CD106+/CD54+) cells were sortedwithMoFlo XDP.The graphs show the fold difference in concentration
of mRNA for Oct-4, Nanog, and Rexo-1 in sorted fractions when compared to unfractionated TNCs (shown as 1). Results are presented as
mean ± SD. Statistically significant differences (𝑃 < 0.05) are shown when compared with TNCs. Analysis was performed three times with
samples prepared from three independent sorts.
low values of FSC and SSC parameters (Figure 1(a)). We
found that especially CD45−/Lin−/CD106+ fraction exhib-
ited morphology of very small cells in comparison with
its hematopoietic counterpart (CD45+/Lin−/CD106+) when
“back-gated” on FSC versus SSC dot-plot (Figure 1(a)).
Moreover, we confirmed the existence of such small cel-
lular objects within both identified populations of CD45−/
Lin−/CD54+ or CD45−/Lin−/CD106+ cells by ImageStream
system (Figure 1(b)).
3.2. Rat BM-Derived CD45−/Lin−/CD106+ Population Con-
tains Developmentally Early rVSELs Expressing Oct-4 and
Nanog Pluripotency Markers. Thus, by employing two stain-
ing and gating strategies on MoFlo XDP cell sorter, we
focused on two subpopulations expected to potentially
contain rVSELs: (1) CD45−/Lin−/CD106+ and (2) CD45−/
Lin−/CD106+/CD54+. We further evaluated the expression
of selected VSEL-related genes (Oct-4, Nanog, and Rexo1)
whose expression we consider as indicator for the potential
presence of rVSELs in such sorted fractions (Figure 2).
Additionally to hematopoietic counterparts (CD45+/Lin−/
CD106+/CD54+ and CD45+/Lin−/CD106+ cells), we also
purified nonhematopoietic fraction (CD45−/Lin−) of rat BM
cells expressing SSEA-1 which has been recently reported as
rat VSEL population by Wu et al. [33]. We planned to pursue
this fraction further in our experiments if enrichment in
mRNA for VSEL-related genes is found within these cells.We
found significantly greater concentration in mRNA for both
vast transcription factors regulating cell pluripotency (Oct-
4A and Nanog) in purified CD45−/Lin−/CD106+ population
of rat BM cells when compared to unfractionated BM cells
(TNCs; input cells) and also to CD45−/Lin−/SSEA-1+ fraction
(Figure 2, Table 2). However, opposite to our initial expecta-
tions, the expression of Oct-4 and Nanog in highly purified
subfraction of CD45−/Lin−/CD106+/CD54+ cells was lower
than in CD45−/Lin−/CD106+ population (Figure 2, Table 2).
These results indicated that CD54 was not a selection marker
for Oct-4-expressing rVSELs and other markers need to be
found to be coexpressedwithCD106 and to enrich for rVSELs
during sorting procedure.
We could also notice some upregulation in mRNA
expression for Oct-4 and Nanog in CD45−/Lin−/SSEA-1+
cells when compared to unpurified BM cells, but it was
rather negligible and significantly lower when comparedwith
Stem Cells International 7
Table 2: Quantitative real time RT-PCR analysis of mRNA expression for genes related to pluripotency in purified populations of rat BM-
derived populations.
Cells fractions
Pluripotent stem cells markers
Oct-4 Nanog Rexo1
Mean ± SD Mean ± SD Mean ± SD
Unfractionated TNCs (control) 1.00 1.00 1.00
CD45−/Lin−/SSEA-1+ 4.58 ± 0.91 15.08 ± 6.67 7.90 ± 3.11
CD45−/Lin−/CD106+ 34.30 ± 17.35 103.89 ± 27.56 9.34 ± 3.51
CD45+/Lin−/CD106+ 2.16 ± 0.91 8.63 ± 2.88 4.90 ± 2.00
CD45−/Lin−/CD106+/CD54+ 3.11 ± 0.31 13.07 ± 2.72 8.15 ± 2.66
CD45+/Lin−/CD106+/CD54+ 8.54 ± 3.85 6.69 ± 0.99 4.87 ± 1.73
Results are presented as values of ΔΔCt (average data based on 3 independent experiments; mean ± SD) when compared with whole unfractionated BM tissue
(control; computed as 1.00).
purified CD45−/Lin−/CD106+ population (Figure 2, Table 2).
The level of mRNA expression for Rexo1 that also represents
transcription factor expressed in pluripotent cells occurred
to be the least discriminative for the tested populations and
was fairly enriched in all three sorted nonhematopoietic
populations (Figure 2, Table 2).Thus, the results indicate that
the expression of CD106, but not CD54 and SSEA-1 antigens,
defines developmentally early population of SCs in rat bone
marrow.
Since our data from gene expression analysis indicated
that the fraction of CD45−/Lin−/CD106+ cells may be
enriched in primitive SCs, we evaluated expression of Oct-4
and Nanog on protein level within (i) CD45−/Lin−/CD106+
subpopulation gated on whole BM cells by ImageStream
X system and we calculated morphological features of
these cells (Figures 3 and 4) as well as in (ii) FACS-
purified CD45−/Lin−/CD106+ fraction by immunocyto-
chemistry (Figure 5). Importantly, in terms of identification
of expression of Oct-4, we employed exclusively antibodies
that bind Oct-4A isoform related to stem cell pluripotency to
focus entirely on SCs with such characteristics (Santa Cruz
Biotechnology, sc-9081, CA, USA).
Both imaging platforms confirmed the existence of
subpopulation of stem cells expressing Oct-4A and Nanog
among CD45−/Lin−/CD106+ fraction of rat BM cells
(Figures 3 and 5). On the other hand, we did not observe any
cells expressing Oct-4 or Nanog among sorted hematopoietic
counterparts (Figure 5). We also directly measured several
morphological features of Oct-4 expressing CD45−/Lin−/
CD106+ rVSELs when compared to other cells including
diameter of individual cells (cell size) as well as N/C ratio
and cytoplasmic area that confirmed primitive stem cell
phenotype of rVSELs (Figure 4). We found that CD45−/
Lin−/CD106+/Oct-4+ rVSELs possess the smallest size,
the highest N/C ratio, and the smallest cytoplasmic area
when compared to CD45−/Lin−/CD106+ rHSCs and TNC
population (Figure 4).
Importantly, only subfraction of CD45−/Lin−/CD106+
cells stained positively for Oct-4A (Figure 5) indicating the
need for further purification of these cells leading eventually
to further enrichment in pluripotent rVSELs.
3.3. Optimized Protocol for Isolation of Rat BM-Derived
rVSELs-Technical Hints. Since we established that
CD45−/Lin−/CD106+ population of rat BM cells exhibit
higher concentration of mRNA for pluripotent stem cell
markers such as Oct-4 and Nanog which was also confirmed
on protein level, we moved to fine-tuning the sorting
protocol for such SCs that would be applicable for isolation
of these cells from both WT and eGFP-expressing rat BM
tissue (Figure 6). We focused on BM tissue derived not only
from WT, but also from transgenic eGFP-expressing rats,
since the potential donor eGFP+ rVSELs may be tracked
following transplantation into WT animals, which would be
important for further studies of their biological properties in
vivo.
Thus, we employed the following directly conjugated
antibodies prior to sorting procedures to avoid any nonspe-
cific binding: (i) Alexa Flour 647/APC-conjugated antibodies
against Lin markers (anti-TCR𝛼𝛽, anti-CD3, anti-CD11b/c,
and anti-CD45RA); (ii) PE-Cy7-conjugated antibody for
CD45, and (iii) PE-conjugated antibody for CD106 (all
antibodies listed in Table 1) that allow for compensation and
sorting also eGFP-expressing cells (Figure 6).
In the first gating step, all events including lymphocytes
and sublymphocyte fraction with FSClow/SSClow parame-
ters (enclosing small cell and debris) were included into
sorting gate R1 (“lymphgate extended into lower values of
FSC”; Figure 6(a)). In the next step of such gating strategy,
doublets were excluded from sorting by employing gating on
FSC-Width versus FSC-Height dot-plot (Figure 6(b)). Single
cells from gate R2 were subsequently analyzed based on
hematopoietic lineages (Lin) markers expression and Lin−
fraction derived from gate R3 (Figure 6(c)) was further visu-
alized based onCD106 expression (Figure 6(d)). CD106+ cells
were finally gated based on CD45 expression on CD45 versus
FSC-H dot-plot which allowed us to distinguish two popula-
tions of (1) rat VSELs (FSClow/SSClow/CD45−/Lin−/CD106+)
and (2) hematopoietic CD45+/Lin−/CD106+ cells consisting
of smaller and larger subfractions (Figure 6(e)). Impor-
tantly, the established new protocol for FACS sorting of
CD106-expressing very small cells from rat bone marrow
allows for isolation of developmentally early SCs expressing
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Figure 3: Expression of Oct-4A and Nanog in selected BM populations on protein level. Representative images of Oct-4A- and Nanog-
expressing CD45−/Lin−/CD106+ cells by ImageStream X system. TNCs were stained for (1) Oct-4A (Alexa Fluor 488, green), CD45 (PE-Cy7,
magenta), and CD106 (PE, orange) (a) and (2) Nanog (Alexa Fluor 647, blue), Lin markers (FITC, green), CD45 (PE-Cy7, magenta), and
CD106 (PE, orange) (b). Cell were stained with Hoechst 33342 to visualize nuclei and analyzed by ISS to detect intranuclear expression of
Oct-4A (a) and Nanog (b) as shown in magnified, combined images. The scale bars indicate 10𝜇m.
Oct-4 and Nanog antigens from tissues of bothWT and GFP
animals.
4. Discussion
Recent evidence indicates that adult murine BM harbors a
multitude of nonhematopoietic stem and progenitor cells
in addition to well described HSCs [34, 35]. Such SC
populations belonging to nonhematopoietic compartment
of BM tissue include mesenchymal stem cells (MSC) [36],
multipotent adult progenitor cells (MAPC) [10], marrow-
isolated adult multilineage inducible cells (MIAMI) [9],
multipotent adult stem cells (MASC) [11], and very small
embryonic-like stem cells (VSEL) [31].
BM-derived murine VSELs have been isolated and char-
acterized based on surface antigens as well as gene expression
as a population of Sca-1+/Lin−/CD45−/Oct-4+/Nanog+ cells
[23]. VSELs morphology and ultrastructure have been also
described indicating their very small size (smaller than ery-
throcytes) and higher N/C ratio which supports their prim-
itive nature [24]. Importantly, several groups have reported
the presence of such SCs in other murine and human tissues
including ovaries and testes [16–22, 28, 29].
In this study, we isolated and antigenically defined
in adult rat BM a population of stem cells with devel-
opmentally early characteristics that we may define as
FSClow/SSClow/CD45−/Lin−/CD106+ cells. Due to a very
small size and the presence of other stem cell-related mor-
phological features accompanied with expression of markers
related to pluripotency including expression of Oct-4 and
Nanog, we consider this population as rat counterpart of
BM-derived murine VSELs. As such we called these cells rat
VSELs (rVSELs).
In the first step, we tested and optimized two different
protocols for sorting rVSELs by flow cytometry. The unique
small size of VSELs requires optimized strategy for sorting
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SD N/C ratio SD
rVSELs 25.99 2.56 5.32 0.39 18.32 3.00 7.88 2.63 2.326 0.776
rHSCs 60.49 5.33 8.39 0.47 33.86 4.79 29.57 4.43 1.145 0.565
rTNCs All cells (singlets) 56.49 20.07 7.79 1.45 30.91 13.4 22.71 10.52 1.361 0.691
Populations: SD SD SD SD N/C ratio SD
rVSELs 29.62 5.79 5.70 0.67 18.94 4.16 10.72 4.46 1.767 0.735
rHSCs 57.91 7.80 8.23 0.60 30.94 2.55 27.03 7.94 1.145 0.336
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Figure 4: Quantitative analysis of morphological features of selected rat BM populations by ImageStream X system. (a) Quantitative analysis
of cell size, nuclear to cytoplasmic (N/C) ratio, and cytoplasmic area of rVSELs when compared to other cell types. Analysis was performed
based on the collected images of following rat BMpopulations: (i) rVSELs: CD45−/Lin−/CD106+ cells expressingOct-4A orNanog (upper and
lower table, resp.); (ii) rHSCs: CD45+/Lin−/CD106+ cells with no expression of Oct-4A and Nanog, and (iii) TNCs (gated as singlets during
the analysis). Analyses were performedwith IDEAS software (Amnis Corp.). Data are shown as average values of each indicated feature within
the cell population (mean± SD). (b) Analytical approach formasking and feature calculation by IDEAS. Images show brightfield (BF), nuclear
(Hoe), and combined (BF-Hoe) images of one example rat BM cell as well as exact masks (cyan) and features (formulas based on the defined
masks) that were optimized and used for the analysis shown in (a). Cell size was expressed as minor cell axis computed within the mask
covering BF image, while cytoplasmic area and N/C ratio were calculated based on the areas of BF and nuclear images (as indicated in red
boxes). All masks and features including their nomenclature represent standard parameters provided by IDEAS software (Amnis Corp.)























Figure 5: Expression of Oct-4A and Nanog in sorted fractions of rVSELs (CD45−/Lin−/CD106+) and rHSCs (CD45+/Lin−/CD106+) by
immunocytochemistry. Both fractions were sorted with MoFlo XDP cell sorter (Beckman Coulter) and further stained for Oct-4A (Alexa
Fluor 488, green) (a) or Nanog (Alexa Fluor 546, red) (b) and analyzed with Leica DMI6000B (ver. AF7000) fluorescent microscope. Nuclei
are stained with DAPI. Intranuclear staining for both transcription factors is visualized on combo images. The scale bars indicate 10𝜇m.
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Figure 6: Optimized protocol for isolation of rVSELs from WT and eGFP-expressing rat BM tissue. Rat BM-derived VSELs were isolated
from full population of BM cells stained for CD45 (PE-Cy7), Lin markers (TCR𝛼𝛽, CD3, CD11b, and CD45RA; Alexa Fluor 647), and CD106
(PE) byMoFlo XDP cell sorter (Beckman Coulter). (a) Total nucleated cells (TNCs) are visualized on dot-plot showing FSC-H versus SSC-H.
(b) Small agranular cells from gate R1 (with extension of lymphgate into low values of FSC; Figure 5(a)) are plotted on FSC-W versus FSC-H
dot-plot to exclude doublets. (c) Single cells from gate R2 are subsequently analyzed for Lin markers expression. (d) Lin− events included in
region R3 are further plotted on dot-plot showing CD106 expression versus side scattered characteristics (SSC-H) of these cells. (e) CD106+
cells from gate R4 are eventually visualized on dot-plot based on their CD45 expression and FSC signal (FSC-H). Rat HSCs are identified as
CD45+/Lin−/CD106+ (region R6), while rVSELs as FSClow/SSClow/CD45−/Lin−/CD106+ cells (region R5).
that includesminimal threshold on instrument and extension
the “lymphgate” into lowest values of FSC signal as described
in several previous studieswhereVSELswere isolated [14, 25].
Based on the established protocols, we focused in our sorting
gating strategy exclusively on small objects including lym-
phocytes and sublymphocyte fraction with FSClow/SSClow
parameters that may enclose very small stem cells. Such
approach in isolation of VSEL from murine and human
specimens has been previously employed and successfully
used by several groups [3, 15, 17, 25, 29] and represents a
crucial step for successful isolation of these rare cells.
In the next step, we selected potential markers for purifi-
cation of rat VSELs including CD54 and CD106 representing
vast surface antigen potentially expressed on subset on
murine VSELs. Although CD54 (ICAM-1) antigen has been
found to be expressed on activated endothelial cells, T and
B cells, monocytes/macrophages, granulocytes, and dendritic
cells [37], it may also be expressed on stem cells [38, 39].
Similarly, CD106 (VCAM-1) may be expressed not only on
mature myeloid cells, splendid dendritic cells, or induced
endothelial cells, but also on more primitive bone marrow





integrin) [41] and the interactions between
these molecules may play an important role in binding
of leukocytes to activated endothelial cells and leukocyte
extravasation at inflammatory sites as well as in stem cell
migration [41, 42].
By employing multi-instrumental flow cytometric
analysis, quantitative RT-PCR, and immunochemistry, we
established that FACS-sorted population of FSClow/SSClow/
CD45−/Lin−/CD106+ rat VSELs expresses several markers
of pluripotency including Oct-4, Nanog, and Rexo1. We
established that isolation protocol described in this study
may be more effective in isolation of developmentally early
SCs when compared to FSClow/SSClow/CD45−/Lin−/CD54+
population or CD45−/SSEA-1+ cells described by Wu and
colleagues [33]. Here, for the first time we report that highly
purified adult rat BM-derived CD45−/Lin−/CD106+ cells
may be enriched in fraction of SCs expressing markers of
pluripotent cells such as Oct-4 and Nanog. Importantly, such
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Table 3: Comparison of major features and phenotype of human and murine VSELs with rat BM-derived VSELs.
Feature Human VSELs[3, 4, 12, 46]
Murine VSEL
[1, 5, 12, 15, 23–25] Rat VSELs
Morphology of “very small SCs”
Cells smaller than red blood cells
in researched typical species
contain large nuclei surrounded
by a narrow rim of cytoplasm
+ + +
Size (by ISS) 6.75 ± 1.04𝜇m 3.63 ± 0.27 𝜇m 5.32 ± 0.39 𝜇m
Frequency (% of TNCs) 0.01% 0.02% 0.03%





Other surface antigen expression
CD133/1+ (AC133+), CD34+,
SSEA-4+, AP+, c-Met+, LIF-R+,
CXCR4+, CD45−, Lin−
Sca-1+, SSEA-1+, AP+, c-Met+,
LIF-R+, CXCR4+, CD45−, Lin−,




Expression of pluripotent SC
transcription factors: Oct-4A and
Nanog
+ + +
(∗) Lin – abbreviation indicating major markers characterizing main fractions of hematopoietic cell lineages present in BM tissue such as erythrocytes,
monocytes, granulocytes, and subfractions of lymphocytes.
CD45−/Lin−/CD106+ population remains still heterogeneous
in terms of the expression of both markers indicating that
further phenotypic characterization has to be performed.
Interestingly, coexpression of CD54 does not indicate
the population of rVSELs with greater Oct-4 and Nanog
expression. Although single small cellular objects were
found within CD45−/Lin−/CD54+ population by ISS, we lost
enrichment in early Oct-4- and Nanog-expressing rVSELs
in CD45−/Lin−/CD106+/CD54+ fraction. The data indicates
that other surface markers will be required in the future
to enrich purification of the Oct-4- and Nanog-expressing
rVSELs.
Importantly, since some cellular debris may be also
sorted during rVSELs purification due to the very small
size expected from stem cells, the imaging cytometry
(ImageStream X; ISS-X) was also employed in our study
to confirm that isolated rVSELs represent cellular nucleated
objects. The ISS technology allows for statistical analysis of
a variety of cellular parameters and for visualization of
cells in suspension during flow analysis via high-resolution
brightfield, darkfield, and fluorescence images collected with
the high resolution [43–45]. Importantly, we have previously
employed imaging cytometry for identification and char-
acterization of VSELs from other specimens proving this
technology as an optimal tool distinguishing real cellular
objects such as small SCs from debris and artifacts present
in different specimens [24, 25].
Interestingly, we confirmed that very small embryonic-
like CD45−/SSEA-1+ stem cells described byWu et al. are also
enriched in mRNA for transcription factor (Oct-4, Nanog,
and Rexo1) but the expression was lower when compared
with purified CD45−/Lin−/CD106+ rVSELs isolated in our
study. Wu et al. described nonhematopoietic CD45−/SSEA-
1+ cells, which were characterized by small size (4-5𝜇m),
large nucleus, small amount of cytoplasm, expression of PSC
transcription factors, and ability to differentiate into the cells
from 3-germ layer under special conditions [33]. Thus, these
observations may strongly suggest that rat CD45−/SSEA-1+
and CD45−/Lin−/CD106+ may overlap that would need to be
further investigated.
5. Conclusions
In conclusion, we identified and characterized in adult rat
bonemarrow a population of very small stem cells expressing
Oct-4A and Nanog markers that shares phenotypic features
of previously identified VSELs. The newly identified fraction
of rat VSELs (FSClow/SSClow/CD45−/Lin−/CD106+) may in
fact correspond to murine and human VSELs based on their
morphology and expression of pluripotent markers such as
Oct-4, Nanog, and Rexo1 on mRNA level and protein levels.
Comparison of human and murine VSELs as well as newly
identified rVSELs is shown in Table 3.
Although our results indicated CD106 as a first positive
selection marker for Oct-4A-expressing rat VSELs, further
antigens need to be found to enrich these unique stem cells
during isolation procedures, when used in coexpression with
CD106. Thus, further efforts are needed to exactly define
multiantigenic profile of BM-derived rVSELs as well as to
further characterize biological properties and functionality of
these newly identified rat stem cells.
However, this is the first study optimizing flow cytometric
sorting strategies for purification of rat BM-derived Oct-
4A+ VSELs from both wild type (WT) and eGFP-expressing
animals for further experimental purposes in this species.The
described phenotype may be employed for further studies
of rVSELs in multiple other rat tissues and organs including
ovaries and testes. Importantly, the donor eGFP-expressing
rVSELs may be followed after transplantation which would
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allow for further studies of biological properties of these cells
in vivo.
Importantly, this study opens new perspectives for study-
ing VSELs in several rat tissues and organs in normal healthy
conditions as well as for examining their potential regen-
erative capacity in several unique rat tissue injury models.
This would provide a new impact on current knowledge
about VSELs including potential regenerative capacity of
these unique SCs, which still need to be investigated in in vitro
as well as in vivo studies.
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